Boston Therapeutics, Inc. (BTHE) Exhibiting PAZ320 at Inaugural Obesity Week 2013 Conference
Boston Therapeutics, a company focusing on the development of drugs using complex carbohydrate chemistry to address diabetes, reported in a news release today it is an exhibitor at the inaugural Obesity Week 2013 Conference in Atlanta, Georgia. The conference, taking place November 13-15, is billed as the world’s largest event on preventing and treating obesity, gathering the world’s leading scientists, clinicians, and surgeons for collaboration, data presentation, and networking.
At the conference, Boston Therapeutics will be in Booth #127, presenting information about its PAZ320, a non-systemic chewable tablet drug which targets enzymes that digest sugar during digestion. The drug therefore reduces the amount of glucose available for absorption by the intestine. Recently PAZ320 was found to help patients with type 2 diabetes manage their post-meal blood sugar levels in a successful FDA Phase 2a clinical trial.
Edward Shea, Vice President of Business Development, Boston Therapeutics, Inc., commented, “Our participation in Obesity Week 2013 — the world’s largest event on obesity treatment and prevention — will further demonstrate Boston Therapeutics’ commitment to those patients suffering from obesity and one of its devastating complications: diabetes.”
According to the American Diabetes Association, over 25 million children and adults in the U.S. have diabetes. Over 25% of that population remains undiagnosed, and 79 million are estimated to be pre-diabetic. In one study-illustration of diabetes’ economic impact, researchers found that people with diagnosed diabetes spend 2.3 times more on medical expenses than people without the condition, after adjusting for population and sex differences.
For more information, visit: www.bostonti.com
Please read full disclaimers at https://disclaimer.missionir.com